[{"data":1,"prerenderedAt":167},["ShallowReactive",2],{"drug-insulin-lispro":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":43,"contraindications":78,"warnings":88,"renal":96,"monitoring":97,"interactions":98,"review":99,"examples":102,"atc":103,"iran":105,"links":112,"populations":128,"usApproval":162},"insulin-lispro",1,{"fa":7,"en":8},"انسولین لیسپرو","Insulin lispro","alimentary-metabolism",{"fa":11,"en":12},"انسولین سریع‌الاثر","Rapid-acting insulin",[14],{"name":15,"market":16},"Humalog","US",[18,19,20],"humalog","هومالوگ","لیسپرو",[22,35],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"u100","injection","sc","100 units\u002FmL (U-100) vial, cartridge or KwikPen",{"amount":28,"unit":29,"perVolumeMl":5},100,"unit",[16],[32],{"source":33,"section":34},"fda-humalog","3",{"id":36,"form":24,"route":25,"label":37,"concentration":38,"markets":40,"refs":41},"u200","200 units\u002FmL (U-200) KwikPen",{"amount":39,"unit":29,"perVolumeMl":5},200,[16],[42],{"source":33,"section":34},[44,62],{"id":45,"disease":46,"label":47,"population":50,"type":51,"unit":52,"dose":53,"refs":57},"t1","type-1-diabetes",{"fa":48,"en":49},"دیابت — دوز فردی، ۱۵ دقیقه قبل یا بلافاصله پس از غذا","Diabetes — individualised, within 15 min before or right after a meal",{},"notCalculated","mg",{"reason":54},{"fa":55,"en":56},"برچسب: دوز بر اساس نیاز متابولیک، پایش قند و هدف درمان فردی شود. زیرجلدی ظرف ۱۵ دقیقه قبل یا بلافاصله پس از غذا؛ معمولاً همراه انسولین پایه. U-200 فقط با قلم مخصوص.","Label: individualise by metabolic needs, glucose monitoring and goals. SC within 15 min before or right after a meal; usually with a basal insulin. U-200 only in its own pen.",[58,60],{"source":33,"section":59},"2.3",{"source":33,"section":61},"2.1",{"id":63,"disease":64,"label":65,"population":68,"type":51,"unit":52,"dose":72,"refs":76},"t2","type-2-diabetes",{"fa":66,"en":67},"دیابت نوع ۲ — دوز فردی همراه غذا","Type 2 diabetes — individualised mealtime dose",{"minAge":69},{"value":70,"unit":71},18,"year",{"reason":73},{"fa":74,"en":75},"برچسب: دوز فردی بر اساس پایش قند؛ زیرجلدی ظرف ۱۵ دقیقه قبل یا بلافاصله پس از غذا.","Label: individualise by glucose monitoring; SC within 15 min before or right after a meal.",[77],{"source":33,"section":59},[79],{"id":80,"severity":81,"text":82,"refs":85},"hypo","block",{"fa":83,"en":84},"هنگام هیپوگلیسمی؛ حساسیت به انسولین یا اجزای فرآورده.","During episodes of hypoglycaemia; hypersensitivity to the insulin or its excipients.",[86],{"source":33,"section":87},"4",[89],{"text":90,"refs":93},{"fa":91,"en":92},"هیپوگلیسمی؛ هیپوکالمی؛ قلم یا سرنگ مشترک بین بیماران ممنوع.","Hypoglycaemia; hypokalaemia; never share pens or syringes.",[94],{"source":33,"section":95},"5",[],[],[],{"status":100,"reviewer":101,"date":101},"unverified",null,[],[104],"A10AB04",{"status":106,"refs":107},"not-found",[108],{"source":109,"section":110,"url":111},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Insulin%20lispro",[113,117,121,125],{"kind":114,"url":115,"label":116},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=020563","BLA020563",{"kind":118,"url":119,"label":120},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f","FDA Humalog",{"kind":122,"url":123,"label":124},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa697021.html","Insulin Lispro Injection",{"kind":126,"url":127,"label":104},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10AB04",{"pregnancy":129,"lactation":138,"pediatric":146,"geriatric":154},{"level":130,"text":131,"quote":134,"refs":135},"caution",{"fa":132,"en":133},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) .",[136],{"source":33,"section":137},"8.1",{"level":130,"text":139,"quote":142,"refs":143},{"fa":140,"en":141},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Available data from published literature suggests that exogenous human insulin products, including insulin lispro, are transferred into human milk.",[144],{"source":33,"section":145},"8.2",{"level":130,"text":147,"quote":150,"refs":151},{"fa":148,"en":149},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of HUMALOG to improve glycemic control have been established in pediatric patients with diabetes mellitus.",[152],{"source":33,"section":153},"8.4",{"level":130,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of patients (n=2,834) in eight clinical studies of HUMALOG, twelve percent (n=338) were 65 years of age or over.",[160],{"source":33,"section":161},"8.5",{"kind":163,"refs":164,"id":116},"BLA",[165],{"source":33,"section":166},"SPL approval \u002F marketing category",1792156182677]